research Response to Tofacitinib Therapy of Eyebrows and Eyelashes in Alopecia Areata
Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
Search
for
Sort by
Research
690-720 / 1000+ results 
research Interleukin 6 and STAT3 Regulate p63 Isoform Expression in Keratinocytes During Regeneration
The conclusion is that the IL-6/STAT3 activation affects p63 expression in healing wounds, which may help in hair follicle regeneration.
research Successful Hair Regrowth in a Korean Patient with Alopecia Universalis Following Tofacitinib Treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Alopecia Universalis Unresponsive to Treatment with Tofacitinib: Report of a Case with a Brief Review of the Literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Frontal Fibrosing Alopecia: A Disease Fascinating for the Researcher, Disappointing for the Clinician and Distressing for the Patient
Frontal Fibrosing Alopecia is a poorly understood condition that is hard to treat and causes distressing hair loss.
research Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Genes and Immune Response in Alopecia Areata: Review of the Alopecia Areata Research Summit First Day Proceedings
Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib treatment for hair loss may worsen acne.
research Tofacitinib for the Treatment of Three Immune-Mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research What’s New in Hair Loss
New treatments for hair loss show promise, but require more research on long-term effects and proper dosing.
research Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Alopecia Areata: A Complex Cytokine-Driven Disease
Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.
research Personalized Medicine in the Field of Inflammatory Skin Disorders
Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
research Atopic Dermatitis And Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Using Artificial Intelligence to Analyze Publicly Available Social Media Posts to Understand Patient Perspectives Toward Specific Treatments of Alopecia Areata
Patients generally feel positive about alopecia areata treatments, but emotions vary by treatment type.
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Peripheral Neuropathy Associated with Tofacitinib Use in Alopecia Universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Tofacitinib Treatment in Children With Rheumatic Diseases: Single-Center Experience
Tofacitinib is a promising treatment for children with rheumatic diseases.
research High Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata
Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.
research Alopecia Areata and Alopecia Areata Incognita
Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
research One of the Best Treatments for Alopecia Areata Remains Unpublished
DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
research Efficacy of Oral Tofacitinib in the Treatment of Lichen Planopilaris
Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
research Efficacy of Tofacitinib in Pediatric Alopecia Universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research Baricitinib (Olumiant) for Severe Alopecia Areata Treatment Recommendations
Olumiant should be covered for severe alopecia areata if certain conditions are met.